Rekuperator Svenska AB owned by VOLVO Technology Transfer Corporation and Avesta Polarit, has successfully developed a completely laser welded recuperator for micro-gas turbine applications. Tests have shown that the thermal performance is very competitive. The recuperator was installed in a 100 kW(e) micro-gas turbine power plant for combined electricity and heat generation by a customer. The recuperator is a primary surface counter flow heat exchanger with cross corrugated duct configuration. The primary heat transfer surface plate patterns are stamped and a pair of the plates are laser welded to form an air cell. The air cells are then stacked and laser welded together to form the recuperator core which is tied between two end beams. Manifolds for air inlet and outlet as well as piping system are welded to the core. Through varying the number of air cells the recuperator core can easily be adapted for micro-gas turbine applications with different output rates of electrical power. The key manufacturing technologies are stamping of the air cell plates and laser welding of the air cells. These processes can be fully automated for mass production at low costs.

Objectives To examine the aggregate rates of antibiotic use at population level and compare these rates over time against historical averages to identify the effect of SARS-CoV-2 and the resulting control measures, upon community prescribing. Methods We collected antibiotic prescriptions and physician office visits from January 1, 2016 to July 21, 2020. We calculated monthly prescription rates stratified by sex, age group, profession, diagnosis type and antibiotic class. We looked at monthly prescription rate as a moving average over time. Using interrupted time series analysis method we estimated the changes in prescription rates after March 2020. Results The moving average of overall monthly prescription rates during January to June of 2020 were below the minimum of the historical years’ moving averages (2016-2019). We observed >30% reduction in overall monthly prescription rates in April, May and July of 2020 compared to the same months of 2019. We observed overall monthly prescription rates experienced a significant level change of -12.79 (p < 0.001) after COVID-19 after March 2020, with the greatest level change of -18.02 among 1-4 years (p<0.001). We estimated an average -5.94 (p<0.001) change in RTI-associated monthly prescription rates after March 2020. Overall prescription rates comparing January – July 2019 and their 2020 counterparts showed a decrease in monthly prescribing ranging from -1 to -5 for: amoxicillin, amoxicillin and enzyme inhibitors, azithromycin, clarithromycin and sulfamethoxazole. Conclusion In BC, Canada, overall and RTI-specific monthly antibiotic prescription rates declined significantly during April to July 2020 compared to the same months in pre-pandemic years.

Introduction:The illicit drug toxicity (overdose) crisis has worsened across Canada; between 2016 and 2021, more than 28,000 individuals have died of drug toxicity.Organ donation from persons who experience drug toxicity death (DTD) has increased in recent years. This study examines whether survival after heart or bilateral-lung transplantation differed by donor cause of death. Methods: We studied transplant recipients in British Columbia who received heart (N = 110) or bilateral-lung (N = 223) transplantation from deceased donors aged 12-70 years between 2013 and 2019. Transplant recipient survival was compared by donor cause of death from drug toxicity or other. Five-year Kaplan-Meier estimates of survival and 3-year inverse probability treatment weighted Cox proportional hazards models were conducted.Results: DTD donors made up 36% (40/110) of heart and 24% (54/223) of bilaterallung transplantations. DTD donors were more likely to be young, white, and male.Unadjusted 5-year recipient survival was similar by donor cause of death (heart: 87% for DTD and 86% for non-DTD, p = .75; bilateral-lung: 80% for DTD and 76% for non-DTD, p = .65). Adjusted risk of mortality at 3-years post-transplant was similar between recipients of DTD and non-DTD donor heart (hazard ratio [HR]: .94, 95% con-

No abstract

IntroductionAllergic conditions, such as asthma, hay fever and eczema, are some of the most common conditions impacting children globally. There is a strong incentive to study their determinants to improve their prevention. Asthma, hay fever and eczema are influenced through the same immunological pathway and often copresent in children (‘the atopic march’). Increasing evidence shows a link between infant antibiotic use and the risk of childhood atopic conditions, mediated through gut microbial dysbiosis during immune system maturation, however, the potential for confounding remains. This study will investigate the relationship between infant antibiotic use and risk of allergic conditions in British Columbian and Manitoban children born over 10 years, adjusting for relevant confounders.Methods and analysisProvincial administrative datasets will be linked to perform comparable retrospective cohort analyses, using Population Data BC and the Manitoba Population Research Data Repository. All infants born between 2001 and 2011 in BC and Manitoba will be included (approximately 460 000 and 162 500 infants, respectively), following up to age 7. Multivariable logistic regression will determine the outcome risk by the fifth birthday among children who did and did not receive antibiotics before their first birthday. Clinical, demographic and environmental covariates will be explored, and sensitivity analyses performed to reduce confounding by indication.Ethics and disseminationThe University of British Columbia Research Ethics Board (H19-03255) and University of Manitoba Ethics Board (HS25156 (H2021:328)) have approved this study. Data stewardship committees for all administrative datasets have granted permissions, facilitated by Population Data BC and the Manitoba Centre for Health Policy. Permissions from the Canadian Health Infant Longitudinal Development Study are being sought for breastfeeding data (CP185). Findings will be published in scientific journals and presented at infectious disease and respiratory health conferences. A stakeholder committee will guide and enhance sensitive and impactful communication of the findings to new parents.